Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: case report and review of the literature

Pediatr Hematol Oncol. 2007 Oct-Nov;24(7):513-24. doi: 10.1080/08880010701533603.

Abstract

Diffuse lymphangiomatosis is a very rare congenital disease, characterized by diffuse or multifocal lymphangioma in the skeletal tissue, spleen, liver, mediastinum, and/or lung. The prognosis is usually poor, especially for children with thoracic lesion, and treatments for the disease are controversial. The authors report a 9-year-old boy with diffuse lymphangiomatosis involving the thorax with pleural effusions, the spleen, and systemic bone. The patient was treated with pegylated interferon alfa-2b, and achieved good clinical and radiological improvement.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Child
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / blood
  • Interferon-alpha / therapeutic use*
  • Lymphangioma / diagnostic imaging
  • Lymphangioma / drug therapy*
  • Lymphangioma / physiopathology
  • Male
  • Polyethylene Glycols
  • Radiography
  • Recombinant Proteins
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Polyethylene Glycols
  • peginterferon alfa-2b